CN102209538B - P70 s6激酶抑制剂和egfr抑制剂的组合治疗剂 - Google Patents

P70 s6激酶抑制剂和egfr抑制剂的组合治疗剂 Download PDF

Info

Publication number
CN102209538B
CN102209538B CN2009801448775A CN200980144877A CN102209538B CN 102209538 B CN102209538 B CN 102209538B CN 2009801448775 A CN2009801448775 A CN 2009801448775A CN 200980144877 A CN200980144877 A CN 200980144877A CN 102209538 B CN102209538 B CN 102209538B
Authority
CN
China
Prior art keywords
fluoro
trifluoromethyl
phenyl
pyrimidine
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801448775A
Other languages
English (en)
Chinese (zh)
Other versions
CN102209538A (zh
Inventor
S.吉加纳奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102209538A publication Critical patent/CN102209538A/zh
Application granted granted Critical
Publication of CN102209538B publication Critical patent/CN102209538B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801448775A 2008-11-11 2009-11-04 P70 s6激酶抑制剂和egfr抑制剂的组合治疗剂 Expired - Fee Related CN102209538B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11327608P 2008-11-11 2008-11-11
US61/113,276 2008-11-11
US61/113276 2008-11-11
PCT/US2009/063189 WO2010056575A1 (en) 2008-11-11 2009-11-04 P70 s6 kinase inhibitor and egfr inhibitor combination therapy

Publications (2)

Publication Number Publication Date
CN102209538A CN102209538A (zh) 2011-10-05
CN102209538B true CN102209538B (zh) 2013-06-12

Family

ID=41664868

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801448775A Expired - Fee Related CN102209538B (zh) 2008-11-11 2009-11-04 P70 s6激酶抑制剂和egfr抑制剂的组合治疗剂

Country Status (11)

Country Link
US (1) US8334293B2 (cg-RX-API-DMAC10.html)
EP (1) EP2355821A1 (cg-RX-API-DMAC10.html)
JP (1) JP2012508240A (cg-RX-API-DMAC10.html)
KR (1) KR20110075015A (cg-RX-API-DMAC10.html)
CN (1) CN102209538B (cg-RX-API-DMAC10.html)
AU (1) AU2009314336B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0921888A2 (cg-RX-API-DMAC10.html)
CA (1) CA2743295A1 (cg-RX-API-DMAC10.html)
EA (1) EA018624B1 (cg-RX-API-DMAC10.html)
MX (1) MX2011005002A (cg-RX-API-DMAC10.html)
WO (1) WO2010056575A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777707A1 (en) 2013-03-11 2014-09-17 Wake Forest University Health Sciences Method of Treating Brain Tumors
MX370448B (es) * 2013-03-11 2019-12-13 Merck Patent Gmbh Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa.
US9457019B2 (en) * 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
US20200237758A1 (en) * 2014-04-04 2020-07-30 Astrazeneca Ab Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
WO2019147934A1 (en) * 2018-01-29 2019-08-01 Sackner Bernstein Jonathan Methods for dopamine modulation in human neurologic diseases
DE102018205152A1 (de) 2018-04-05 2019-10-10 Glatt Ingenieurtechnik Gmbh Verfahren und Reaktor zur Herstellung von Partikeln
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679439A (zh) * 2007-05-11 2010-03-24 伊莱利利公司 P70 s6激酶抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AU2005322085B2 (en) * 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
CA2626456C (en) * 2005-10-18 2018-01-09 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679439A (zh) * 2007-05-11 2010-03-24 伊莱利利公司 P70 s6激酶抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Doherty L.;et al.egfr和mtor抑制剂联合应用治疗复发性恶性胶质瘤的先导性研究.《世界核心医学期刊文摘(神经病学分册)》.2006,(第12期),21页. *

Also Published As

Publication number Publication date
MX2011005002A (es) 2011-05-25
BRPI0921888A2 (pt) 2015-12-29
CA2743295A1 (en) 2010-05-20
WO2010056575A1 (en) 2010-05-20
EA201170682A1 (ru) 2011-10-31
EP2355821A1 (en) 2011-08-17
JP2012508240A (ja) 2012-04-05
AU2009314336A1 (en) 2010-05-20
KR20110075015A (ko) 2011-07-05
AU2009314336B2 (en) 2013-09-12
EA018624B1 (ru) 2013-09-30
US8334293B2 (en) 2012-12-18
US20110207752A1 (en) 2011-08-25
CN102209538A (zh) 2011-10-05

Similar Documents

Publication Publication Date Title
US20240360085A1 (en) Glucose Uptake Inhibitors
EP2148880B1 (en) P70 s6 kinase inhibitors
CN114656482B (zh) 作为egfr抑制剂的大环杂环类化合物及其应用
AU2010310786B2 (en) AKT inhibitors
TWI588141B (zh) 經取代之苄基吲唑
AU2009314336B2 (en) P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
CN102209539B (zh) P70 s6激酶抑制剂和mtor抑制剂的组合治疗剂
CN113416181A (zh) 喹唑啉类衍生物及其用途
EP2012587A2 (en) Cancer treatment method
CN110857292A (zh) 一种egfr激酶抑制剂及其制备方法和应用
CN113004285B (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
US20110301185A1 (en) Cancer treatment method
CA3101370A1 (en) Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer
KR20220065811A (ko) 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제
WO2008063853A2 (en) Cancer treatment method
WO2026090333A1 (en) Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
CN116490507A (zh) 用于治疗癌症的杂环包缩合cdc7激酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130612

Termination date: 20131104